Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Maria Filomena Ruberto"'
Autor:
Francesco Marongiu, Dimitrios Marco Ntoukas, Luigi Barberini, Maria Filomena Ruberto, Maria Sebastiana Piras, Maria Conti, Maria Luisa Di Martino, Mario Mura, Silvia Marongiu, Maria Luigia Vannini, Mattia Lillu, Monica Piras, Daniela Fanni, Lara Fenu, Carmen Porcu, Doris Barcellona, Gavino Faa, Terenzio Congiu
Publikováno v:
Journal of Public Health Research (2021)
Background: Clot characterization is, to the present days, a multimodal approach: scanning the clot by electron microscopy (SEM) is helpful for the visualization of fibrin structure along with laboratory parameters such as the clot waveform analysis
Externí odkaz:
https://doaj.org/article/f6f1c447511c487d8a0722cde325819a
Publikováno v:
Methods in Molecular Biology ISBN: 9781071631744
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::777ae0f2329a10ba8e8ed9f335ef2c80
https://doi.org/10.1007/978-1-0716-3175-1_9
https://doi.org/10.1007/978-1-0716-3175-1_9
Autor:
Marina Di Pino, Maria Filomena Ruberto, Giulia Anna Maria Luigia Costanzo, Davide Firinu, Maria Sebastiana Piras, Mario Nicola Mura, Stefano Del Giacco, Ferdinando Coghe, Francesco Marongiu, Doris Barcellona
Chronic spontaneous urticaria (CSU) is a disorder characterized by wheals and/or angioedema. The coagulation cascade and inflammation pathways are closely linked together. The aim of our study was first to investigate the dynamics of clot formation i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b29056d0fe2122d3bb137bdf4627071c
https://doi.org/10.21203/rs.3.rs-1217804/v1
https://doi.org/10.21203/rs.3.rs-1217804/v1
Autor:
Doris Barcellona, Elvira Grandone, Francesco Marongiu, Sebastiana Maria Piras, Maria Luigia Vannini, Giovanni Favuzzi, Maria Filomena Ruberto
Publikováno v:
Hämostaseologie. 39:398-403
Introduction Factor XI (FXI) deficiency is a bleeding disorder which causes a bleeding tendency after trauma or surgery. An inhibitor may be acquired secondary to replacement therapy. Aim To study on genetical and functional grounds a family admitted
Autor:
Mattia Lillu, Carmen Porcu, Gavino Faa, Terenzio Congiu, Mario Nicola Mura, Dimitrios Marco Ntoukas, Daniela Fanni, Luigi Barberini, M. Conti, Silvia Marongiu, Maria Luigia Vannini, Francesco Marongiu, Maria Filomena Ruberto, Lara Fenu, Monica Piras, Doris Barcellona, Maria Sebastiana Piras, Maria Luisa Di Martino
Publikováno v:
Journal of Public Health Research (2021)
Background Clot characterization is, to the present days, a multimodal approach: scanning the clot by electron microscopy (SEM) is helpful for the visualization of fibrin structure along with laboratory parameters such as the clot waveform analysis (
Autor:
Maria Filomena Ruberto, Francesco Marongiu, Orazio Sorbello, Luigi Demelia, Doris Barcellona, Alberto Civolani
Publikováno v:
International Journal of Laboratory Hematology. 41:118-123
Introduction Prothrombin time is thought to be unreliable in cirrhotic patients to predict the risk of bleeding. We investigated whether prothrombin time ratio was an independent risk factor for bleeding alongside its clot waveform analysis. Methods
Autor:
Francesco Marongiu, Antonella Mandas, Elisabetta M. Cianchetti, Doris Barcellona, Antonella Mameli, Mariagrazia Porru, Maria Filomena Ruberto
Publikováno v:
Clinical Chemistry and Laboratory Medicine (CCLM). 56:448-453
Background: Hospitalized patients with acute medical conditions have higher venous thromboembolism (VTE) risk. A patient with a final Padua Prediction Score (PPS) of ≥4 is considered to be at high risk for VTE. The aim of this study was to investig
Autor:
Doris Barcellona, Orazio Sorbello, Luigi Demelia, Alberto Civolani, Francesco Marongiu, Maria Filomena Ruberto
Publikováno v:
International Journal of Laboratory Hematology. 39:369-374
SummaryIntroduction Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are abnormal but unreliable in cirrhotic patients to express their risk of bleeding. However, these patients may also suffer from thrombotic episodes. In order
Autor:
Maria Elisabetta Cianchetti, Francesco Marongiu, Mario Musu, Paola Schirru, Doris Barcellona, Antonella Mameli, Maria Filomena Ruberto, Mariagrazia Porru
Publikováno v:
International Journal of Hematology. 105:532-535
Dabigatran is an oral, direct thrombin inhibitor approved by international regulatory agencies for stroke prevention in patients with paroxysmal or persistent non-rheumatic atrial fibrillation (AF). The benefits of dabigatran are widely described, bu
Publikováno v:
International Journal of Laboratory Hematology. 40:e15-e16